About Us
Founded in 2016, Maxwell Biosciences is a preclinical stage drug platform company actively developing an entirely new CLAROMER® biotechnology platform which creates low molecular weight compounds which mimic peptides and are functionally distinct from macromolecules due to the ease of penetrating membranes.
This novel biotechnology mimics the power and flexibility of natural antimicrobial peptides - with the pharmacological advantages of a low molecular weight molecule - to safely and permanently inactivate viruses, bacteria, fungi and biofilms. Maxwell is led by a world-class team of scientists and executives.
Maxwell Biosciences recently announced confirmation by U.S. government-funded labs that Maxwell's lead drug candidate has direct virucidal action against SARS-CoV-2.
Animal data shows that the compounds are well tolerated in vivo. Prior to this, Maxwell's drugs have been confirmed to show direct activity against the structure of the Herpes Simplex Virus (HSV-1), all ESKAPE antibiotic resistant bacteria, and many fungal species. Our drug platform is supported by a granted patent portfolio and is strongly positioned to act as a key player in the fight against emergent viral pandemics.